Posted by Michael Wonder on 20 Nov 2023
Bristol Myers Squibb and 2seventy bio provide update on US FDA review of sBLA for Abecma (idecabtagene vicleucel) in earlier lines of therapy for triple-class exposed relapsed or refractory multiple myeloma
20 November 2023 - Bristol Myers Squibb and 2seventy bio today announced the US FDA Oncologic Drugs Advisory Committee will meet to review data supporting the supplemental biologics license application for Abecma (idecabtagene vicleucel) for earlier lines of triple-class exposed relapsed or refractory multiple myeloma based on results from the pivotal Phase 3 KarMMa-3 study.
The date of the Oncologic Drugs Advisory Committee meeting has not yet been confirmed by the FDA.
